Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Inclusion Criteria: * Aged 18 to 50 years on the day of first study vaccination (study product administration) ("18 to 50" means from the day of the 18th birthday to the day before the 51th birthday) * Inform concent form has been signed and dated * Able to attend all scheduled visits and to comply with all trial procedures * Documented seropositivity for HIV-1 infection based on the Brazilian HIV Guidelines' laboratory criteria (i.e., two positive results obtained from different and independent determination methods) or detectable HIV-1 viral load results in the past * Stable HIV condition according to Brazilian HIV Guidelines (i.e., with both CD4 count \> 350 cells/mm3 and sustainable and undetectable HIV viral load \[\< 50 copies/mL\]) for at least 1 year before consent * Stable antiretroviral (ART) regimen based on local HIV protocol for at least 1 year before consent. * Previous exposure to dengue confirmed by rapid diagnostic test (RDT) or dengue IgG ELISA Exclusion Criteria: * Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination) * Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation …